Inventor
XIONG CAI
Inventor
US
Overview
Patents· 7 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations32%
C07DHeterocyclic compounds32%
A61KPreparations for medical, dental or toiletry purposes27%
C07CAcyclic or carbocyclic compounds5%
Y02ATechnologies for adaptation to climate change5%
PatentTitleYear
11,654,136Phosphoinositide 3-kinase inhibitor with a zinc binding moiety202311,597,732Phosphoinositide 3-kinase inhibitors with a zinc binding moiety202311,560,377Fused amino pyridine as HSP90 inhibitors202311,306,1021,3-di-substituted ketene compound and application thereof202211,267,8022,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof202211,261,195Phosphoinositide 3-kinase inhibitors with a zinc binding moiety202211,135,205Phosphoinositide 3-kinase inhibitor with a zinc binding moiety2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2023Patents assigned to CURIS INC (5)· patent assignee history
2021–2023Based in US· patent location history
2022Patents assigned to BEBETTER MED INC (2)· patent assignee history
2022Based in CN· patent location history
2023Patents assigned to GURIS INC (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| CURIS INC | 5 | 2021–2023 |
| BEBETTER MED INC | 2 | 2022 |
| GURIS INC | 1 | 2023 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 5 | 2021–2023 |
| CN | 2 | 2022 |